Serum VEGF and IL-6 Levels in Colorectal Cancer Patients
Author Information
Author(s): Eldesoky Ayman Shouma Ashraf, Mosaad Yousef, Elhawary Amira
Primary Institution: Mansoura University, Egypt
Hypothesis
The study aimed to investigate the clinical relevance of serum vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) in patients with colorectal cancer (CRC).
Conclusion
Preoperative measurement of serum VEGF and IL-6 may serve as useful non-invasive diagnostic indicators associated with advanced clinical stage and tumor metastasis in CRC patients.
Supporting Evidence
- CRC patients had significantly higher VEGF and IL-6 levels than healthy controls.
- Patients with advanced clinical stage had higher levels of VEGF and IL-6 than those with early clinical stage.
- Patients with metastatic disease had higher VEGF and IL-6 levels than those with localized disease.
Takeaway
Doctors can check certain substances in the blood to help tell if someone with colorectal cancer has a more serious case.
Methodology
Preoperative serum levels of VEGF and IL-6 were measured in 35 CRC patients and 30 healthy controls using enzyme-linked immuno-assay.
Potential Biases
Potential biases may arise from the selection of control subjects and the exclusion criteria applied.
Limitations
The study was limited to a specific patient population and may not be generalizable to all CRC patients.
Participant Demographics
The study included 35 CRC patients (26 males, 9 females) with an average age of 49 years, and 30 healthy controls (23 males, 7 females) with an average age of 59 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website